CPP
RNAC icon

Crow Point Partners’s Cartesian Therapeutics RNAC Stock Holding History

Crow Point Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-573
Closed -$50K – 128
2018
Q4 		$50K Hold
573
– – 0.01% 118
2018
Q3 		$267K Buy
573
+44
+8% +$17.7K 0.05% 128
2018
Q2 		$204K Buy
529
+517
+4,308% +$183K 0.04% 112
2018
Q1 		$4K Sell
12
-52
-81% -$14.8K ﹤0.01% 258
2017
Q4 		$20K Buy
+64
New +$28K ﹤0.01% 245

Other funds holding RNAC

Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Crow Point Partners's RNAC Position: Q1 2019 in Review

Crow Point Partners sold out of Cartesian Therapeutics (RNAC) in Q1 2019, closing a stake of 573 shares — an estimated $50K sold.

Crow Point Partners first reported a position in RNAC in Q4 2017 and held it in 5 quarters. The position peaked at $267K in Q3 2018. 56 funds tracked by Wall St. Rank hold RNAC as of Q1 2019.

  • Crow Point Partners reported no remaining Cartesian Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Crow Point Partners sold 573 Cartesian Therapeutics shares in Q1 2019, an estimated $50K.
  • Crow Point Partners first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 5 quarters.
  • Crow Point Partners's Cartesian Therapeutics position peaked at $267K in Q3 2018.
  • 56 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2019.

Based on Crow Point Partners's 13F filing for Q1 2019, filed 15 May 2019.